Brief: GBS Inc - Qtrly Loss Per Share Of $0.27

Intelligent Bio Solutions

14/05/2021 13:52

May 14 (Reuters) - Gbs Inc  GBS.O :
    * GBS INC SAYS ANTICIPATE EMERGENCY USE APPROVAL FOR
SARS-COV-2
ANTIBODY BIOSENSOR TEST FROM FDA IN SECOND HALF OF 2021
    * GBS INC SAYS AS OF MARCH 31, CO'S CASH, CASH EQUIVALENTS,
AND
MARKETABLE SECURITIES TOTALED ABOUT $14.2 MILLION
    * GBS INC SAYS CASH EQUIVALENTS AND MARKETABLE SECURITIES
WILL BE
SUFFICIENT TO COVER EXPENSES AND CAPITAL REQUIREMENTS THROUGH AT
LEAST Q2 OF 2022

Source text for Eikon:  ID:nGNX2Fm7k1 
Further company coverage:  GBS.O 

 ((Reuters.Briefs@thomsonreuters.com;))